Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at Guggenheim

Guggenheim reissued their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report issued on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Several other equities research analysts have also issued reports on CMPX. Craig Hallum began coverage on shares of Compass Therapeutics in a research note on Friday, February 13th. They issued a “buy” rating and a $15.00 price objective for the company. D. Boral Capital reissued a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Raymond James Financial restated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Citigroup began coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “outperform” rating for the company. Finally, William Blair reissued an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $5.33 on Tuesday. The firm has a market cap of $959.88 million, a PE ratio of -12.40 and a beta of 1.48. The firm’s 50 day moving average price is $5.92 and its 200 day moving average price is $5.00. Compass Therapeutics has a twelve month low of $1.33 and a twelve month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, March 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, sell-side analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after acquiring an additional 7,592 shares during the period. Creative Planning bought a new position in shares of Compass Therapeutics in the second quarter worth about $30,000. Flagship Harbor Advisors LLC bought a new position in shares of Compass Therapeutics in the fourth quarter worth about $32,000. Strs Ohio acquired a new position in shares of Compass Therapeutics during the 1st quarter worth about $34,000. Finally, Apollon Wealth Management LLC bought a new stake in Compass Therapeutics during the 3rd quarter valued at approximately $35,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.